MGNX

Macrogenics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 2

stock price surged significantly

Revenue Plunges

EPS Beats Expectation

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MGNX

Macrogenics, Inc.

A biopharmaceutical company that focused on innovative monoclonal antibody-based therapeutics for the treatment of cancer

Industry

Biological Technology

Established Date

08/14/2000

Listing Date

10/10/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

341

Fiscal Year Ends

12-31

Website

www.macrogenics.com

Security Type

Common stock

Office address

9704 Medical Center Drive, Rockville, Maryland 20850

Business

Introduction

Macrogenics, Inc., was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, manufacture and commercialization of innovative antibody therapies for the treatment of cancer. The company develops product candidates through its proprietary suite of next-generation antibody technology platforms and believes this platform can improve the performance of monoclonal antibodies and antibody-derived molecules. With knowledge of disease biology and immune-mediated mechanisms, the company has identified these product candidates that may address the challenges posed by specific diseases that cannot be treated by existing therapies. The company not only develops differentiated molecules for new cancer targets, but also improves the efficacy of marketed drugs.

Company Financials

EPS

MGNX has released its 2024 Q4 earnings. EPS was reported at -0.25, versus the expected -0.59, beating expectations. The chart below visualizes how MGNX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MGNX has released its 2024 Q4 earnings report, with revenue of 19.35M, reflecting a YoY change of 80.53%, and net profit of -15.42M, showing a YoY change of 66.53%. The Sankey diagram below clearly presents MGNX’s revenue sources and cost distribution.